Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 13 of 30
Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty
NCT03977454
Guanfacine to Improve Substance Use Outcomes in Women
NCT03980184
Pragmatic RCT of SBIRT-PM
NCT04062214
A Virtual Reality Videogame for E-cigarette Prevention in Teens
NCT04054765
Neurobiological Responses in Alcoholism and Early Trauma
NCT04128228
The Evaluation of a School Climate Videogame Intervention
NCT04025294
THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis
NCT04199468
Neuroimmune Effects of Opioid Administration
NCT03801629
Voiding Assessment Based on Minimum Spontaneous Void of 150 mL Compared to Retrograde Fill Method After Female Pelvic Floor Reconstructive Surgery
NCT03539107
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders
NCT03946111
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment
NCT03926052
CBT4CBT With Spanish Alcohol Users
NCT03474588
Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease
NCT03978156
Text Messaging in Patients on Adjuvant Endocrine Therapy for Breast Cancer
NCT03949270
Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy
NCT03889756
Daytime Bright Light, Circadian Abnormalities, and Delirium in Medical ICU Patients
NCT03684460
Effect of Allopregnanolone on Stress-induced Craving
NCT04015869
Cognitive Function and Pain Threshold in People Who Are Methadone Maintained
NCT04027166
Impact of Cigarette and E-cigarette Flavors on Adult Smoking Behavior
NCT04009850
Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study
NCT04057001
Families Coping Together With Alzheimer's Disease
NCT04642885
Measuring the Neuroimmune Response to Alcohol
NCT04251221
Ivabradine for Rate Control in Permanent Atrial Fibrillation
NCT03987204
Patient Reported Outcomes for Opioid Use Disorder
NCT03985163
The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA
NCT03965130
Application of Electrical Impedance Myography (EIM) as a Potential Biomarker of Idiopathic Inflammatory Myopathies
NCT03918356
Evaluating the Feasibility and Efficacy of a Real-time Smoking Intervention Using Wearable Technology
NCT04172623
Effects of E-Cigarette Flavors on Adults TCORS 2.0
NCT03635333
Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia
NCT03705286
Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare
NCT03910543
Brief ROC Training Effects on Alcohol Drinking
NCT03928626
Intervention to Reduce Diaper Need and Increase Use of Pediatric Preventive Care
NCT03490045
Peer Online Motivational Interviewing for Sexual and Gender Minority Male Survivors
NCT03794986
Effects of Psilocybin in Concussion Headache
NCT03806985
Vitamin D and Cocaine Administration
NCT04826133
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment
NCT03924193
The Role of Neuroactive Steroids in Stress, Drug Craving and Drug Use in Cocaine Use Disorders
NCT03953612
Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol
NCT03580525
Opioid and Pain Cognition
NCT04132609
Implementation and Dissemination of an Evidence-Based Tobacco Product Use Prevention Videogame Intervention With Adolescents
NCT03815591
Stress Reduction Study for Partners of Early Stage Dementia
NCT03691428
Creation of a Digital Heart Failure Registry Using a Novel Mobile Health Platform: HUGO-HF
NCT03810638
Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure
NCT03440970
Pilot of Pragmatic SBIRT Study
NCT03307967
Yale Wellness Project
NCT03229577
Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)
NCT03386487
Inpatient Versus Outpatient Foley Cervical Ripening Study
NCT03725397
Imaging Synaptic Density in Cocaine and Opiate Addiction In Vivo Using 11UCB-J PET
NCT03527485
Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes
NCT03582956
Evaluation and Management of Metabolic Bone Disease in Kidney Transplant Recipients
NCT03958409
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.